Vardenafil
- CAS No.
- 224785-90-4
- Chemical Name:
- Vardenafil
- Synonyms
- Levitra;VARDENAFIL HCL TRIHYDRATE;FADINAF;Vardenafil powder;Vardenafil (Leviitra);Vivanza;BAY38-9456;VARDENAFIL;Sildelafil;Fardenafil
- CBNumber:
- CB2321327
- Molecular Formula:
- C23H32N6O4S
- Molecular Weight:
- 488.6
- MDL Number:
- MFCD07773094
- MOL File:
- 224785-90-4.mol
Melting point | 230-235°C |
---|---|
Density | 1.37 |
vapor pressure | 0.001Pa at 71.34℃ |
Flash point | 9℃ |
storage temp. | Sealed in dry,Store in freezer, under -20°C |
solubility | >22.5mg/mL in DMSO |
form | Powder |
pka | 9.86±0.20(Predicted) |
color | White to off-white |
Water Solubility | 7mg/L at 20℃ |
BCS Class | 2 |
InChIKey | NOIHTGOGFDFCBN-UHFFFAOYSA-N |
SMILES | N12C(CCC)=NC(C)=C1C(=O)N=C(C1=CC(S(N3CCN(CC)CC3)(=O)=O)=CC=C1OCC)N2 |
LogP | 2.5 at 23℃ |
FDA UNII | UCE6F4125H |
ATC code | G04BE09 |
SAFETY
Risk and Safety Statements
Symbol(GHS) | GHS02,GHS06,GHS08 |
---|---|
Signal word | Danger |
Hazard statements | H225-H301+H311+H331-H370 |
Precautionary statements | P210-P260-P280-P301+P310-P311 |
Hazard Codes | F,Xn |
Risk Statements | 11-20/21/22-36 |
Safety Statements | 16-36/37 |
RIDADR | UN1230 - class 3 - PG 2 - Methanol, solution |
WGK Germany | 1 |
Vardenafil price More Price(8)
Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|---|
Sigma-Aldrich | V-902 | Vardenafil dihydrochloride solution 1.0?mg/mLinmethanol(asfreebase),ampuleof1?mL,certifiedreferencemateri | 224785-90-4 | 1mL | $171 | 2024-03-01 | Buy |
American Custom Chemicals Corporation | API0008769 | VARDENAFIL 95.00% | 224785-90-4 | 10MG | $255.15 | 2021-12-16 | Buy |
AK Scientific | E429 | Vardenafil | 224785-90-4 | 10mg | $98 | 2021-12-16 | Buy |
Matrix Scientific | 168056 | Vardenafil | 224785-90-4 | 1g | $472 | 2021-12-16 | Buy |
Medical Isotopes, Inc. | D34389 | Vardenafil-d5HCl | 224785-90-4 | 1mg | $675 | 2021-12-16 | Buy |
Vardenafil Chemical Properties,Uses,Production
Description
Vardenafil is a new PDE5 inhibitor launched for oral treatment of male erectile dysfunction and it has significant structural similarity with sildenafil (Viagra?), which was the first PDE5 inhibitor introduced in 1998 for this indication. Vardenafil is synthesized in three steps starting with a cyclization reaction of 2-ethyoxybenzamidine with 2-butyramidopropionic acid and ethoxyallyl chloride to construct the imidazotriazine ring system, followed by sulfonation to the corresponding sulfonyl chloride and subsequent condensation with 1-ethylpiperazine. The potency of PDE5 inhibition by vardenafil (IC50=0.7 nM) is ~10 times greater than that of sildenafil (IC50=6.6 nM). Vardenafil is typically administered in single doses of 10 and 20 mg. The time to reach maximum plasma concentration is 0.75 h, which is slightly shorter than those of sildenafil (tmax=1.16 h) and tadalafil (tmax=2h), and the half-life is 4–5 h. Although it is almost completely absorbed following oral administration, the mean absolute bioavailability of a 10 mg dose is ~15%, resulting from extensive first pass metabolism. Vardenafil is metabolized in the liver primarily by CYP3A4 and is eliminated mainly in feces. In clinical studies, 10–20 mg doses of vardenafil was well tolerated and efficacious in patients with ED of various severities, including subjects with comorbidities such as diabetes mellitus or hypertension or hyperlipidemia. The side-effect profile of vardenafil is similar to that of sildenafil, with headache, flushing, dyspepsia and nasal congestion being the most common adverse events. Vardenafil has systemic vasodilatory properties, which can cause transient decrease in supine blood pressure; however, it does not appear to translate into clinical effects. The mean maximum decreases in supine systolic blood pressure following 20 and 40 mg vardenafil were 6.9 and 4.3 mmHg, respectively, when compared to placebo. However, single and multiple oral doses of vardenafil up to 40 mg produced no clinically relevant changes in the ECGs of normal male volunteers.
Originator
Bayer AG (Germany)
Uses
erectil dysfunction;PDE5 inhibitor
Uses
Vardenafil Hydrochloride Trihydrate (cas# 330808-88-3) has therapeutic applications and used in cosmetics and personal care products.
Definition
ChEBI: The sulfonamide resulting from formal condensation of the sulfo group of 4-ethoxy-3-(5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4(1H)-one-2-yl)benzenesulfonic acid and the secondary amino group of 4-ethylpiperazine.
brand name
Levitra
Flammability and Explosibility
Non flammable
Clinical Use
Treatment of erectile dysfunction
Drug interactions
Potentially hazardous interactions with other drugs
Alpha-blockers: enhanced hypotensive effect - avoid
for 6 hours after alpha-blockers (max dose 5 mg).
Antifungals: concentration increased by
ketoconazole, and itraconazole - avoid concomitant
use.
Antivirals: concentration increased by fosamprenavir,
indinavir and ritonavir- avoid with indinavir and
ritonavir; increased risk of ventricular arrhythmias
with saquinavir - avoid; avoid with telaprevir, use
tipranavir with caution.
Cobicistat: concentration of vardenafil possibly
increased - reduce dose of vardenafil.
Grapefruit juice: concentration possibly increased -
avoid concomitant use.
Nicorandil: possibly enhanced hypotensive effect -
avoid concomitant use.
Nitrates: possibly enhanced hypotensive effect -
avoid concomitant use.
Riociguat: enhanced hypotensive effect - avoid
concomitant use.
Metabolism
Vardenafil is metabolised in the liver primarily by
cytochrome P450 isoenzymes CYP3A4 (the major route)
as well as CYP3A5 and CYP2C isoforms. The major
metabolite produced by desethylation of vardenafil also
has some activity.
Vardenafil is excreted as metabolites mainly in the faeces
(91 to 95
%), and to a lesser extent in the urine.
Vardenafil Preparation Products And Raw materials
Supplier | Tel | Country | ProdList | Advantage | |
---|---|---|---|---|---|
Firsky International Trade (Wuhan) Co., Ltd | +8615387054039 | admin@firsky-cn.com | China | 436 | 58 |
Wuhan Cell Pharmaceutical Co., Ltd | +86-13129979210 +86-13129979210 | sales@cellwh.com | China | 376 | 58 |
Wuhan Ruichi Technology Co., Ltd | +8613545065237 | admin@whrchem.com | China | 161 | 58 |
Shaanxi Cuikang Pharmaceutical Technology Co., Ltd | +86-18791163155 +86-13119157289 | 13119157289@163.com | China | 2972 | 58 |
Dorne Chemical Technology co. LTD | +86-86-13583358881 +8618560316533 | Ethan@dornechem.com | China | 3137 | 58 |
HangZhou RunYan Pharma Technology Co.,LTD. | +8618882027439 | sales2@runyanpharma.com | China | 304 | 58 |
Jinan Million Pharmaceutical Co., Ltd | 0531-68659554 +8613031714605 | info@millionpharm.com | China | 205 | 58 |
Shaanxi Franta Biotechnology Co., Ltd | +86-13082019107 +86-13082019107 | admin@flanderff.com | China | 225 | 58 |
Sigma Audley | +86-15937194204 +86-18126314766 | nova@sh-teruiop.com | China | 491 | 58 |
Hebei Mojin Biotechnology Co.,Ltd | +86-15028179902 | angelia@hbmojin.com | China | 1069 | 58 |
View Lastest Price from Vardenafil manufacturers
Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
---|---|---|---|---|---|---|---|---|
2024-09-22 | Vardenafil;Fardenafil
224785-90-4
|
US $0.00-0.00 / g | 10g | 99% HPLC | 10000 | HangZhou RunYan Pharma Technology Co.,LTD. | ||
2024-09-22 | Vardenafil
224785-90-4
|
US $2.00-1120.00 / g | 10g | 99% | 100kg | Wuhan Cell Pharmaceutical Co., Ltd | ||
2024-09-22 | Vardenafil
224785-90-4
|
US $1.00 / g | 1g | 99% | 100kg | Dorne Chemical Technology co. LTD |
- Vardenafil;Fardenafil
224785-90-4
- US $0.00-0.00 / g
- 99% HPLC
- HangZhou RunYan Pharma Technology Co.,LTD.
- Vardenafil
224785-90-4
- US $2.00-1120.00 / g
- 99%
- Wuhan Cell Pharmaceutical Co., Ltd
- Vardenafil
224785-90-4
- US $1.00 / g
- 99%
- Dorne Chemical Technology co. LTD